2024, April 22

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

Development of a new class of viral vectors – Anellovectors – with potential to deliver DNA payloads across broad tissue types in redosable manner 

Anellovectors demonstrate expanded payload capacity and expression of therapeutic relevancy in retina of non-human primates

Cambridge, Mass. April 22, 2024 — Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024. These presentations showcase the immense promise of a new class of viral vectors from Ring’s AnellogyTM platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.

Oral Presentation details below:

Title: Anellovectors, a Gene Delivery Platform Based on Commensal Human Anelloviruses, Have the Potential to Evade the Immune System and Deliver DNA Payloads to a Broad Range of Tissues in a Redosable Manner

Speaker: Chris Wright, MD, PhD, Chief Medical Officer at Ring Therapeutics

Session Title and Location: Emerging Viral Vectors – Ballroom 4, Baltimore Convention Center

Presentation Date and Time: Thurs, May 9, 5:00 – 5:15 PM ET

Poster Presentation details below:

Title: Anellovectors: Expanding the Payload Capacity of Anellovirus-Based Vectors Beyond the Wild-Type Genome Capacity

Abstract Number:  450

Presenter: Cato Prince

Presentation Location, Date, and Time: Exhibit Hall, Wed, May 8, 12:00 PM ET

 

Title: Anellovector Derived from Human Retinal Pigment Epithelium Delivers and Expresses a Therapeutically Relevant DNA Payload in the Retina of Nonhuman Primates

Abstract Number: 444

Presenter: Parmi Thakker

Presentation Location, Date, and Time: Exhibit Hall, Wed, May 8, 12:00 PM ET

About Ring Therapeutics

Ring is pioneering a new class of targeted medicines that deliver more. Ring’s Vector Conjugate platform, derived from commensal viruses found in healthy human tissues, exhibits unprecedented modularity and is unencumbered by limitations of traditional vector technologies. Ring’s Vector Conjugates carry small molecules (Vector Drug Conjugates or VDCs) or oligonucleotides (Vector Oligo Conjugates or VOCs) with controllable targeting for applications ranging from oncology to genetic disorders. Ring’s VDCs and VOCs unlock new payloads, payload combinations, and target possibilities. To learn more, visit https://www.ringtx.com/ or follow us on X (Twitter) and LinkedIn.

Press Contacts

Ring Therapeutics Media

Jacqueline Wickwire

LifeSci Communications

617-901-2854